RE:RE:RE:Little sedi action.Like Merck (MSD), and other Big Pharma players who are facing a looming patent cliff and the patent expiration of their blockbuster drugs, Pfizer is on the M&A hunt for new external assets.
Given that the early research activities of mRNA vaccines in the treatment of solid tumors is beginning to gain Big Pharma's attention, ONCY's oncolytic virus pelareorep as a late stage immune molecule platform technique in the treatment of various cancers, is increasingly the kind of biological M&A target that Big Pharma is presently seeking.